Open AccessAssociation between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response
Author(s) -
Xie Xiaohu,
Gu Jun,
Zhuang Dingding,
Zhou Yun,
Chen Xiaoyu,
Shen Wenwen,
Li Longhui,
Liu Yue,
Xu Wenjin,
Hong Qingxiao,
Xu Zemin,
Chen Weisheng,
Zhou Wenhua,
Liu Huifen
Publication year - 2022
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24750
Subject(s) - methadone maintenance , single nucleotide polymorphism , genotyping , medicine , opioid , logistic regression , snp , pharmacology , genotype , methadone , oncology , bioinformatics , biology , gene , genetics , receptor
Objective Genetic variations can affect individual response to methadone maintenance treatment (MMT) for heroin addiction. The A118G variant (rs1799971) in the mu opioid receptor gene (OPRM1) is a potential candidate single nucleotide polymorphism (SNP) for personalized MMT. This study determined whether rs1799971 is related to MMT response or dose. Methods We recruited 286 MMT patients from a Han Chinese population. The rs1799971 genotype was determined via TaqMan genotyping assay. The genetic effect of this SNP on MMT response or dose was evaluated using logistic regression. A meta‐analysis was performed to merge all available data to evaluate the role of rs1799971 in MMT using RevMan 5.3 software. Results No statistical significance was observed in the association between the OPRM1 rs1799971 and MMT response or dose in our Chinese cohort. Meta‐analysis indicated that the OPRM1 A118G variation was not significantly associated with MMT response or dose requirement. Conclusion The results suggest that rs1799971 in OPRM1 might not play a critical role alone in influencing MMT response or dose.